Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Akoya Biosciences, Inc.

Akoya Biosciences Reports First Quarter 2025 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA QTRX
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Reports Third Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Reports Second Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Reports First Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Tickers AKYA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS